Furiex Confirms Takeda Launches LIOVEL LD and LIOVEL HD, a Fixed Dose Combination of NESINA and ACTOS, for Type 2 Diabetes in Japan
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today confirmed that Takeda Pharmaceutical Company Limited has launched two dosages of LIOVEL®, a fixed dose combination tablet of NESINA® and ACTOS® (pioglitazone HCL), in Japan for the treatment of Type 2 diabetes.
Furiex developed NESINA, which is a member of the dipeptidyl peptidase IV (DPP-4) inhibitor class, in collaboration with Takeda's wholly-owned subsidiary, Takeda San Diego, Inc. LIOVEL LD and LIOVEL HD contain 25 mg alogliptin/15 mg pioglitazone and 25 mg alogliptin/30 mg pioglitazone, respectively.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.